ORPHA:624190
Paraneoplastic isolated brainstem encephalitis
Also known as: Paraneoplastic isolated rhombencephalitis · Paraneoplastic isolated rhomboencephalitis
Publications
1
8th percentile
Trials
0
Interventional, condition-specific
Researchers
5
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare autoimmune encephalitis characterized by various phenotypes depending on the region of the brainstem that is involved; patients are present with gaze palsies (in midbrain involvement), facial palsy or vertical gaze palsies (in pontine involvement), dysarthira, dysphagia or central hypoventilation (in medullary involvement). Additional clinical features may also involve pyramidal symptoms and gait impairment.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0850104
- UMLS:C5680406
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1 matched papers (1 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 207 for broader category encephalitis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1
1 paper have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1 in the last 10 years · high confidence · 8th percentile (publications denominator)
Phrase hits: 1 · MeSH hits: 0
Who's working on it?
5
Distinct author names in 1 sampled paper — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Golenia A1 paper · 2025
Department of Neurology, Medical University of Warsaw, Poland.
Papers in Europe PMC - 02Kostera-Pruszczyk A1 paper · 2025
Department of Neurology, Medical University of Warsaw, Poland.
Papers in Europe PMC - 03Olejnik P1 paper · 2025
Department of Neurology, Medical University of Warsaw, Poland.
Papers in Europe PMC - 04
- 05Zakrzewska-Pniewska B1 paper · 2025
Department of Neurology, Medical University of Warsaw, Poland.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 207 trials are registered for encephalitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 26 October 2026 · last trial check 26 October 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5498 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
207 interventional trials matched encephalitis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: encephalitis
207
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05586581·RECRUITING·SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
Conditions: HIV Associated Neurocognitive Disorder · HIV Dementia · HIV Encephalitis · Healthy·Matched via name phrase
- NCT05393492·RECRUITING·Regulating Emotions and Behaviors After Brain Injury
Conditions: Acquired Brain Injury · Stroke/ Cerebrovascular Accident (Ischemic or Hemorrhagic) · Brain Tumor (After Recovery) · Encephalitis·Matched via name phrase
- NCT07088822·NOT YET RECRUITING·A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers
Conditions: Venezuelan Equine Encephalitis · Venezuelan Equine Encephalitis Virus Infection·Matched via name phrase
- NCT06867991·RECRUITING·Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Conditions: Anti-N-Methyl-D-Aspartate Receptor Encephalitis·Matched via name phrase
- NCT07584525·RECRUITING·Dexamethasone in Tick-borne Encephalitis
Conditions: Tick-Borne Encephalitis·Matched via name phrase
- NCT07526493·RECRUITING·Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Conditions: Multiple Sclerosis (MS) · Neuromyelitis Optica Spectrum Disorder (NMOSD) · Autoimmune Encephalitis (AE) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)·Matched via name phrase
- NCT07432113·RECRUITING·Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis/Encephalitis Panel Based on Clinical Syndrome and Cerebrospinal Fluid Parameters: a Diagnostic Stewardship Proposal.
Conditions: Meningitis · Encephalitic Infection · Encephalitis · Meningitis, Fungal·Matched via name phrase
- NCT07337785·RECRUITING·CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Conditions: Relapsing or Refractory Multiple Sclerosis (MS) · Myasthenia Gravis (MG) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Autoimmune Encephalitis (AE)·Matched via name phrase
- NCT06079294·RECRUITING·Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
Conditions: Autoimmune Encephalitis·Matched via name phrase
- NCT07686042·NOT YET RECRUITING·Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
Conditions: Autoimmune Encephalitis (AE) · Autoimmune Cerebellitis·Matched via name phrase
- NCT06939166·RECRUITING·Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
Conditions: Neuromyelitis Optica Spectrum Disorders · Myasthenia Gravis · Multiple Sclerosis · Chronic Inflammatory Demyelinating Polyradiculoneuropathy·Matched via name phrase
- NCT05198661·RECRUITING·Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection
Conditions: Paraneoplastic Neurological Syndromes or Autoimmune Encephalitis·Matched via name phrase
- NCT07093333·RECRUITING·A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
Conditions: Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE) · Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease · Autoimmune Encephalitis·Matched via name phrase
- NCT07131683·NOT YET RECRUITING·hUC-MSC-Exo Therapy for Autoimmune Encephalitis
Conditions: Autoimmune Encephalitis·Matched via name phrase
- NCT06515106·RECRUITING·Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease
Conditions: Limbic Encephalitis With LGI1 Antibodies·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Paraneoplastic isolated brainstem encephalitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Paraneoplastic isolated brainstem encephalitis" OR "Paraneoplastic isolated rhombencephalitis" OR "Paraneoplastic isolated rhomboencephalitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Paraneoplastic isolated brainstem encephalitis" OR "Paraneoplastic isolated rhombencephalitis" OR "Paraneoplastic isolated rhomboencephalitis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"encephalitis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T19:16:56.773Z
